Covovax now available for children in India: SII CEO Adar Poonawalla

Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday said that the Covid-19 vaccine Covovax is now available in India for children.

Topics
Coronavirus Vaccine | Serum Institute of India

ANI 

Adar Poonawalla, chief executive officer (CEO) of Serum Institute of India
Adar Poonawalla, chief executive officer (CEO) of Serum Institute of India (Photo: PTI image)

(SII) CEO Adar Poonawalla on Tuesday said that the COVID-19 vaccine Covovax is now available in India for children.

He also hailed Prime Minister Narendra Modi for his vision of providing another vaccine for children.

Covovax (Novavax), is now available for children in India. This is the only vaccine manufactured in India that is also sold in Europe and has an efficacy of 90 per cent. This is in line with Prime Minister Narendra Modi's vision of providing yet another vaccine to protect our children," he said in a tweet.

Last week, the National Technical Advisory Group on Immunisation (NTAGI) approved the Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17.

However, the Drugs Controller General of India's (DCGI) subject expert committee has sought more data from the Pune-based (SII) on the Covovax vaccine for the age group of 7-12 years.

COVID-19 vaccination for minors in India started from January 3 onwards for those in the 15-18 age group with Bharat Biotech's Covaxin. The drive later expanded on March 16 to include children aged above 12 for Biological E's Corbevax.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Tue, May 03 2022. 18:40 IST
RECOMMENDED FOR YOU